Johnson & Johnson Expects 2026 Sales To Hit Almost $100 Billion

Benzinga01-21

Johnson & Johnson (NYSE:JNJ) on Wednesday reported a fourth-quarter 2025 adjusted earnings of $2.46 per share, up 20.6% year over year, beating the consensus of $2.44.

The pharmaceutical and medtech giant reported sales of $24.56 billion, up 9.1% year over year and beating the consensus of $24.16 billion.

Operational growth was 7.1%, and adjusted operational growth was 6.1%.

Innovative Medicine sales increased 10% or 7.9% operationally to $15.76 billion. Fiscal 2025 sales increased 6% to $60.40 billion.

2025 operational sales grew 5.3%, with net acquisitions and divestitures positively impacting growth by 1.2% primarily due to Caplyta.

Growth was driven primarily by Darzalex (daratumumab), Carvykti (ciltacabtagene autoleucel), Erleada (apalutamide), and Rybrevant/Lazcluze in oncology, Tremfya (guselkumab) and Simponi/Simponi Aria in immunology, and Spravato (esketamine) in neuroscience.

Growth was partially offset by an approximate (1,040) basis points impact from Stelara in Immunology.

Cancer drug sales increased to $6.86 billion, up 24.8% (+21.9% operational). Immunology sales declined to $3.86 billion, a 8.9% decrease (or 10.3% on an operational basis).

MedTech sales increased 7.5% to $8.80 billion. 2025 operational sales grew 5.4%, with net acquisitions and divestitures positively impacting growth by 1.1% primarily due to Shockwave.

Growth was driven primarily by electrophysiology products and Abiomed in Cardiovascular, and wound closure products in General Surgery.

Johnson & Johnson, in its earnings presentation, highlighted that its cancer cell therapy Carvykti and Shockwave each generated annual sales of over $1 billion.

The company said it has 28 platforms with at least $1 billion in annual revenues.

Outlook

Johnson & Johnson issued fiscal 2026 adjusted earnings guidance of $11.43-$11.63, compared to the consensus of $11.45.

The company expects 2026 sales of $99.50 billion-$100.5 billion compared to the consensus of $98.89 billion.

Price Action: Johnson & Johnson shares were down 0.90% at $216.24 during premarket trading on Wednesday. The stock is trading near its 52-week high of $220.11, according to Benzinga Pro data.

Photo by Tada Images via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment